期刊
PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY
卷 51, 期 6, 页码 519-529出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/10826068.2020.1839907
关键词
Fc; albumin fusion; PASylation; PEGylation; plasma half-life extension; XTENylation
Currently, various techniques have been developed to enhance the pharmacokinetic profile of therapeutic proteins, such as chemical bonding to polymers, hyper glycosylation, Fc fusion, human serum albumin fusion, and recombinant PEG mimetics. These techniques mainly fall into three strategies, including endosomal recycling of neonatal Fc receptor, decrease in receptor-mediated clearance, and increase in hydrodynamic radius through chemical and genetic modifications. Novel PEG mimetic peptides like proline/alanine/serine repeat sequences have been designed to overcome the drawbacks of previous technologies.
Nowadays, proteins are frequently administered as therapeutic agents in human diseases. However, the main challenge regarding the clinical application of therapeutic proteins is short circulating plasma half-life that leads to more frequent injections for maintaining therapeutic plasma levels, increased therapy costs, immunogenic reactions, and low patient compliance. So, the development of novel strategies to enhance the pharmacokinetic profile of therapeutic proteins has attracted great attention in pharmaceuticals. So far, several techniques, each with their pros and cons, have been developed including chemical bonding to polymers, hyper glycosylation, Fc fusion, human serum albumin fusion, and recombinant PEG mimetics. These techniques mainly classify into three strategies; (i) the endosomal recycling of neonatal Fc receptor which is observed for immunoglobulins and albumin, (ii) decrease in receptor-mediated clearance, and (iii) increase in hydrodynamic radius through chemical and genetic modifications. Recently, novel PEG mimetic peptides like proline/alanine/serine repeat sequences are designed to overcome pitfalls associated with the previous technologies. Biodegradability, lack of or low immunogenicity, product homogeneity, and a simple production process, currently make these polypeptides as the preferred technology for plasma half-life extension of therapeutic proteins. In this review, challenges and pitfalls in the pharmacokinetic enhancement of therapeutic proteins using PEG-mimetic peptides will be discussed in detail. [GRAPHICS] .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据